PAVmed (PAVM) 10-Q 19 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document And Entity Information
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		36,759,128
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 4,097,520	$ 8,222,119
Prepaid expenses and other current assets	257,363	238,040
Total current assets	4,354,883	8,460,159
Equipment, net	51,001	36,271
Total assets	4,405,884	8,496,430
Current liabilities
Accounts payable	1,800,453	1,738,837
Accrued expenses and other current liabilities	540,521	1,330,746
Senior Secured Convertible Note issued December 31, 2018, at fair value - (face value principal of $4,369,000 and $7,750,00 as of September 30, 2019 and December 31, 2018, respectively)	4,471,535	7,903,000
Total liabilities	6,812,509	10,972,583
COMMITMENTS AND CONTINGENCIES (NOTE 3)
Stockholders' Deficit
Common stock, par value $0.001; 100,000,000 shares authorized; 36,556,178 and 27,142,979 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	36,556	27,143
Additional paid-in capital	43,251,674	32,619,282
Accumulated deficit	(47,402,814)	(36,992,911)
Total PAVmed Inc Stockholders'Deficit	(1,886,269)	(2,314,641)
Noncontrolling interest	(520,356)	(161,512)
Total Stockholders' Deficit	(2,406,625)	(2,476,153)
Total Liabilities and Stockholders' Deficit	4,405,884	8,496,430
Series B Convertible Preferred Stock [Member]
Stockholders' Deficit
Preferred stock, par value $0.001, 20,000,000 shares authorized	$ 2,228,315	$ 2,031,845

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Face value of principal	$ 4,369,000	$ 775,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	36,556,178	27,142,979
Common stock, shares outstanding	36,556,178	27,142,979
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,135,482	1,069,941
Preferred stock, shares outstanding	1,135,482	1,069,941

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenue
General and administrative expense		1,724,265	1,395,980	5,331,130	4,366,438
Research and development expense		1,519,415	1,172,844	4,375,425	2,884,873
Total operating expenses		3,243,680	2,568,824	9,706,555	7,251,311
Loss from operations		(3,243,680)	(2,568,824)	(9,706,555)	(7,251,311)
Other income (expense)
Interest expense - Senior Secured Note			(707,714)		(1,708,322)
Change in fair value - Senior Secured Convertible Note		379,229		(340,830)
Debt extinguishment loss - Senior Secured Convertible Note		(406,858)		(666,670)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series A-1 Warrants					(349,796)
Series W Warrants Exchange Offer - April 5, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series W Warrants					(766,456)
Unit Purchase Options (UPOs) Exchange Offer - August 22, 2018 - incremental fair value - UPO-Z issued-upon-exchange of UPO-W			(2,120)		(2,120)
Modification - Series Z Warrant Agreement - June 1, 2018					(1,140,995)
Change in fair value - Series A Warrants derivative liability					(96,480)
Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability					64,913
Other income (expense), net		(27,629)	(709,834)	(1,007,500)	(3,999,256)
Loss before provision for income tax		(3,271,309)	(3,278,658)	(10,714,055)	(11,250,567)
Provision for income taxes
Net loss - before noncontrolling interest		(3,271,309)	(3,278,658)	(10,714,055)	(11,250,567)
Net loss attributable to noncontrolling interest		186,349	32,431	500,622	113,631
Net loss - attributable to PAVmed Inc.		(3,084,960)	(3,246,227)	(10,213,433)	(11,136,936)
Less: Series B Convertible Preferred Stock dividends		(68,129)	(64,897)	(200,402)	(138,926)
Less: Series A-1 Convertible Preferred Stock dividends					(25,148)
Less: Series A Convertible Preferred Stock dividends	[1]				(26,487)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock					(726,531)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock					199,241
Net loss attributable to PAVmed Inc. common stockholders		$ (3,153,089)	$ (3,311,124)	$ (10,413,835)	$ (11,854,787)
Net loss per share - attributable to PAVmed Inc. - basic and diluted		$ (0.10)	$ (0.12)	$ (0.35)	$ (0.53)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted		$ (0.10)	$ (0.12)	$ (0.36)	$ (0.57)
Weighted average common shares outstanding - basic and diluted	[2],[3]	31,030,929	26,538,632	29,211,694	20,827,519
[1]	The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective peripresented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to September 30, 2018, and for each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018.
[2]	Basic weighted average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
[3]	The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Series A Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2017		$ 1,032,650		$ 14,551	$ 14,012,053	$ (17,907,611)		$ (2,848,357)
Balance, shares at Dec. 31, 2017	249,667	357,259		14,551,234
Underwritten public offering of common stock, net of offering cost				$ 2,650	4,272,011			4,274,661
Underwritten public offering of common stock, net of offering cost, shares				2,649,818
Equity Subscription Rights Offering, net of offering cost				$ 9,000	9,199,326			9,208,326
Equity Subscription Rights Offering, net of offering cost, shares				9,000,000
Exercise - common stock purchase warrant, net of offering costs				$ 309	20,604			20,913
Exercise - common stock purchase warrant, net of offering costs, shares				308,602
Exchange Offer - March 15, 2018		$ (1,032,650)	$ 1,707,244		1,406,640	(726,531)		1,354,703
Exchange Offer - March 15, 2018, shares	(249,667)	(357,259)	975,568
Exchange Offer - April 5, 2018					766,456			766,456
Series Z Warrant Modification					1,140,995			1,140,995
Exchange Offer - August 22, 2018					2,120			2,120
Issue common stock - conversion of Series B Convertible Preferred Stock			$ (58,319)	$ 33	58,286
Issue common stock - conversion of Series B Convertible Preferred Stock, shares			(33,325)	33,325
Dividends - Series B Convertible Preferred Stock			$ 318,023			(318,023)
Dividends - Series B Convertible Preferred Stock, shares			106,045
Dividends - Series A Convertible Preferred Stock						(7,099)		(7,099)
Dividends - Series A Convertible Preferred Stock, shares
Issue of common stock of majority-owned subsidiary							1,812	1,812
Stock-based compensation					869,437			869,437
Stock-based compensation of majority-owned subsidiary					8,962		21,250	30,212
Unit Purchase Options Exchange Offer - August 22, 2018								2,120
Issue common stock - registered offerings, net
Issue common stock - registered offerings, net, shares
Net loss						(11,136,936)	(113,631)	(11,250,567)
Balance at Sep. 30, 2018			$ 1,966,948	$ 26,543	31,756,890	(30,096,200)	(90,569)	3,563,612
Balance, shares at Sep. 30, 2018			1,048,288	26,542,979
Balance at Jun. 30, 2018			$ 1,707,244	$ 26,510	31,384,984	(26,524,851)	(72,054)	6,521,833
Balance, shares at Jun. 30, 2018			975,568	26,509,654
Issue common stock - conversion of Series B Convertible Preferred Stock			$ (58,319)	$ 33	58,286
Issue common stock - conversion of Series B Convertible Preferred Stock, shares			(33,325)	33,325
Dividends - Series B Convertible Preferred Stock			$ 318,023			(318,023)
Dividends - Series B Convertible Preferred Stock, shares			106,045
Dividends - Series A Convertible Preferred Stock						$ (7,099)		$ (7,099)
Dividends - Series A Convertible Preferred Stock, shares
Issue of common stock of majority-owned subsidiary							$ 943	$ 943
Stock-based compensation					306,171			306,171
Stock-based compensation of majority-owned subsidiary					5,329		12,973	18,302
Unit Purchase Options Exchange Offer - August 22, 2018					2,120			2,120
Net loss						(3,246,227)	(32,431)	(3,278,658)
Balance at Sep. 30, 2018			$ 1,966,948	$ 26,543	31,756,890	(30,096,200)	(90,569)	3,563,612
Balance, shares at Sep. 30, 2018			1,048,288	26,542,979
Balance at Dec. 31, 2018			$ 2,031,845	$ 27,143	32,619,282	(36,992,911)	(161,512)	$ (2,476,153)
Balance, shares at Dec. 31, 2018			1,069,941	27,142,979
Underwritten public offering of common stock, net of offering cost, shares								5,480,000
Dividends - Series B Convertible Preferred Stock			$ 196,470			(196,470)
Dividends - Series B Convertible Preferred Stock, shares			65,541
Stock-based compensation					1,023,952			1,023,952
Stock-based compensation of majority-owned subsidiary					11,552		141,778	153,330
Unit Purchase Options Exchange Offer - August 22, 2018
Issue common stock - registered offerings, net				$ 5,480	$ 5,373,422			$ 5,378,902
Issue common stock - registered offerings, net, shares				5,480,000
Issue common stock - Upon partial conversions of Senior Secured Convertible Note				$ 3,850	$ 4,156,113			$ 4,159,963
Issue common stock - Upon partial conversions of Senior Secured Convertible Note, shares				3,850,427
Issue common stock - Employee Stock Purchase Plan				$ 83	67,353			67,436
Issue common stock - Employee Stock Purchase Plan, shares				82,772
Net loss						(10,213,433)	(500,622)	(10,714,055)
Balance at Sep. 30, 2019			$ 2,228,315	$ 36,556	43,251,674	(47,402,814)	(520,356)	(2,406,625)
Balance, shares at Sep. 30, 2019			1,135,482	36,556,178
Balance at Jun. 30, 2019			$ 2,161,523	$ 34,139	40,518,952	(44,251,062)	(342,727)	(1,879,175)
Balance, shares at Jun. 30, 2019			1,113,201	34,139,220
Dividends - Series B Convertible Preferred Stock			$ 66,792			(66,792)
Dividends - Series B Convertible Preferred Stock, shares			22,281
Stock-based compensation					318,266			318,266
Stock-based compensation of majority-owned subsidiary					3,247		8,720	11,967
Issue common stock - Upon partial conversions of Senior Secured Convertible Note				$ 2,334	2,343,856			2,346,190
Issue common stock - Upon partial conversions of Senior Secured Convertible Note, shares				2,334,186
Issue common stock - Employee Stock Purchase Plan				$ 83	67,353			67,436
Issue common stock - Employee Stock Purchase Plan, shares				82,772
Net loss						(3,084,960)	(186,349)	(3,271,309)
Balance at Sep. 30, 2019			$ 2,228,315	$ 36,556	$ 43,251,674	$ (47,402,814)	$ (520,356)	$ (2,406,625)
Balance, shares at Sep. 30, 2019			1,135,482	36,556,178

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss - before noncontrolling interest ("NCI")	$ (3,278,658)	$ (10,714,055)	$ (11,250,567)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense		10,328	6,244
Stock-based compensation	324,473	1,177,282	899,649
Change in fair value - Senior Secured Convertible Note		340,830
Debt extinguishment - Senior Secured Convertible Note		666,670
Interest expense added to principal - Senior Secured Note			194,570
Interest expense accrued - Senior Secured Note			201,867
Interest expense - amortization of debt discount - Senior Secured Note			1,117,315
Series A and Series A-1 Exchange Offer - March 15, 2018			349,796
Series W Warrants Exchange Offer - April 5, 2018			766,456
Unit Purchase Options Exchange Offer - August 22, 2018	2,120		2,120
Modification expense - Series Z Warrant - June 1, 2018			1,140,995
Change in fair value - Series A Warrants derivative liability			96,480
Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability			(64,913)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(19,323)	(31,513)
Accounts payable		61,616	771,537
Accrued expenses and other current liabilities		(790,225)	31,327
Net cash flows used in operating activities		(9,266,877)	(5,768,637)
Cash flows from investing activities
Purchase of equipment		(25,058)	(23,464)
Net cash flows used in investing activities		(25,058)	(23,464)
Cash flows from financing activities
Proceeds - issue of common stock - registered offerings		5,480,000
Payment - offering costs - registered offerings		(101,098)
Proceeds - issue of common stock in an underwritten public offering			4,388,099
Payment - offering costs - underwritten public offering			(113,438)
Proceeds - issue units - equity subscription rights offering			9,437,000
Payment - offering costs - equity subscription rights offering			(228,674)
Payment - Senior Secured Convertible Note - bi-monthly non-installment payments - cash		(279,002)
Proceeds - issue common stock - Employee Stock Purchase Plan		67,436
Proceeds - issue common stock - majority-owned subsidiary			1,812
Proceeds - issue of common stock upon exercise of warrants, net			20,913
Payment - Series A Convertible Preferred Stock Dividends			(7,099)
Net cash flows provided by financing activities		5,167,336	13,498,613
Net (decrease) increase in cash		(4,124,599)	7,706,512
Cash, beginning of period		8,222,119	1,535,022
Cash, end of period	$ 9,241,534	$ 4,097,520	$ 9,241,534

The Company and Description of

The Company and Description of the Business	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Description of the Business	Note 1 — The Company and Description of the Business PAVmed Inc. (“PAVmed” or the “Company”) is a highly-differentiated multi-product technology medical device company organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. Since inception on June 26, 2014, the Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. On May 8, 2018, Lucid Diagnostics Inc., a majority-owned subsidiary of the Company, was incorporated in the State of Delaware, and on May 12, 2018, Lucid Diagnostics Inc. entered into a license agreement with Case Western Reserve University (“CWRU”) with respect to the intellectual property and proprietary technologies referred to as EsoCheck™ and “EsoGuard™”. To date, the Company has not recognized revenue. The ability to generate revenue depends upon the Company’s ability to successfully complete the development, obtain regulatory approval, and to initiate commercialization of its product candidates. Currently, the Company’s activities are focused principally on obtaining FDA clearance and initializing commercialization of the lead product candidates, including CarpX™, EsoGuard™, EsoCheck™, and PortIO™, along with advancing additional product candidates through their respective research and development phase, including DisappEAR™ and NextFlo TM Collectively, PAVmed Inc. and Lucid Diagnostics Inc. have proprietary rights to the trademarks used herein, including, among others, PAVmed™, Lucid Diagnostics™, Caldus™, CarpX™, DisappEAR™, EsoCheck™, EsoGuard™, EsoCheck™ Cell Collection Device™, EsoCheck™ CCD™, EsoCheck™ Technology, NextCath™, NextFlo™, PortIO™, and “Innovating at the Speed of Life” ™. Solely as a matter of convenience, trademarks and trade names referred to herein may or may not be accompanied with the requisite marks of “™” or “®”, however, the absence of such marks is not intended to indicate, in any way, either of PAVmed Inc. or Lucid Diagnostics Inc. will not assert, to the fullest extent possible under applicable law, its rights or the rights to such trademarks and trade names.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the minority ownership interest in the Company’s majority-owned subsidiary Lucid Diagnostics Inc. and the corresponding noncontrolling interest. The condensed balance sheet as of December 31, 2018, which has been derived from audited financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and related notes thereto as of and for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC. Going Concern The provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Presentation of Financial Statements - Going Concern The Company anticipates incurring operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating losses as it completes the development of its products, seeks regulatory approvals and clearances of such products, and begin to commercially market such products. These factors, which have existed since inception, are expected to continue, and raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued. The Company’s ability to fund its operations is dependent upon management’s plans, which include raising additional capital, refinance the debt upon maturity, obtaining regulatory approvals for its products currently under development, commercializing and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance the Company will be successful in these efforts. The Company’s unaudited condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern. Recent Accounting Standards Adoption of new accounting Standard In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) Recently issued accounting standards, not yet adopted: In June 2018, the FASB issued its Accounting Standards Update (“ASU”) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07), which, upon the effective date, will result in non-employee stock-based compensation to be within the scope of ASC-718, and will supersede ASC 505-50. A principal change of the new guidance is to eliminate the ASC 505-50 required periodic fair value remeasure (“mark-to-market”) and use of the “contractual term” as an input to the Black-Scholes option pricing model to calculate the estimated fair value of stock options issued to non-employees, in favor of the ASC 718 one-time measurement of the grant date fair value and use of an “expected term” as such valuation input, for non-employee stock-based compensation expense, as is currently done for employee stock-based compensation expense. The amended ASC-718 non-employee stock-based compensation provisions are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within such fiscal year, and for all other companies for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606). With respect to the Company and its majority-owned subsidiary, the amended ASC-718 non-employee stock-based compensation provisions are required to be adopted by no later than January 1, 2020, resulting from the Company’s “JOBS Act EGC Election” as discussed Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Additionally, the Company, under its “JOBS Act EGC Accounting Standards Election”, adopted ASC 606 as of January 1, 2019, which is the required adoption date of ASC 606 for private companies. At this time, the Company and its majority-owned subsidiary continue to apply the guidance of ASC-505-50 with respect to non-employee stock-based compensation, subject-to the future adoption date of the amended ASC-718 provisions with respect to non-employee stock-based compensation. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) - Part I - Accounting for Certain Financial Instruments with Down-Round Features, and Part II - Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 3 — Commitments and Contingencies Office Leases The Company’s corporate office lease is on a month-to-month basis, with a 5% per annum increase in the monthly lease payment effective February 1 of each year, and the lease agreement may be cancelled with three months written notice. Total rent expense incurred under the corporate office space lease arrangement was $32,992 and $98,453 for the three and nine months ended September 30, 2019, respectively and $31,331 and $93,675 for the three and nine months ended September 30, 2018, respectively. As of September 30, 2019, the Company’s future minimum lease payments for the corporate office lease on a month-to-month basis are estimated to be approximately $136,000 for the period October 1, 2019 to September 30, 2020. Subsequent to September 30, 2019, the Company entered into two separate lease arrangements for office space, including a lease agreement for the period October 16, 2019 to September 30, 2020 and a lease agreement for the period November 1, 2019 to April 30, 2020. The minimum lease payments under both lease agreements is an aggregate of approximately $47,500. EsoGuard™ Clinical Trials - Agreement with Clinical Research Agreement In September 2019, the Company, through its majority-owned subsidiary Lucid Diagnostics Inc., entered into an agreement with a clinical research organization (“CRO”) in connection with EsoGuard™ clinical trials, referred to as the EsoGuard™ CRO Agreement. The CRO will assist the Company with conducting two concurrent clinical trials referred to as the “EsoGuard™ screening study” and the “EsoGuard™ case control study”. The term of the EsoGuard™ CRO Agreement is from the September 2019 effective date to the conclusion of the respective clinical trials, but not to exceed 60 months from the effective date of the EsoGuard™ CRO Agreement. The CRO agreement may be cancelled with sixty days written notice, without an early termination fee. Under the CRO agreement, the Company is required to fund an on-account deposit of $643,000 with the CRO, with such on-account deposit refundable to the Company. In September 2019, $200,000 of the on-account deposit was paid and is included in the accompanying condensed consolidated balance sheet as of September 30, 2019 in the line item captioned Prepaid expenses and other current assets. The remaining balance of the on-account deposit is scheduled to be paid in the three months ended December 31, 2019. The Company has recognized as research and development expense approximately $104,000 in the three and nine months ended September 30, 2019 with respect to the EsoGuard™ CRO Agreement. Legal Proceedings In the ordinary course of our business, particularly as we begin commercialization of our products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company does not believe it is currently a party to any other pending legal proceedings. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 4 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (“PAVmed Inc. 2014 Equity Plan”), adopted by the Company’s board of directors and stockholders in November 2014, is designed to enable the Company to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire a proprietary interest in the Company. The PAVmed Inc. 2014 Equity Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards, and other stock-based awards subject to limitations under applicable law. All awards under the PAVmed Inc. 2014 Equity Plan are subject to approval by the compensation committee of the Company’s board of directors. A total of 7,951,081 shares of common stock of PAVmed Inc. are reserved for issuance under the PAVmed Inc. 2014 Equity Plan, with 2,598,406 shares available for grant as of September 30, 2019, exclusive of 500,854 PAVmed Inc. stock options previously granted outside the PAVmed Inc. 2014 Equity Plan. PAVmed Inc 2014 Equity Plan - Stock Options PAVmed Inc. 2014 Equity Plan - Stock Options Number Stock Options Weighted Average Exercise Price Aggregate Remaining Contractual Term (Years) Outstanding stock options at December 31, 2018 3,327,140 $ 3.68 $ — Granted 1,875,000 $ 1.00 Exercised — $ — Forfeited (48,611 ) $ 5.00 Outstanding stock options at September 30, 2019 5,153,529 $ 2.70 $ — 8.4 Vested and exercisable stock options at September 30, 2019 2,942,544 $ 3.62 $ — 7.7 Unvested stock options at September 30, 2019 2,210,985 $ 1.46 $ — The aggregate intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of September 30, 2019 and December 31, 2018 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. During the nine months ended September 30, 2019, an aggregate of 1,875,000 stock options were granted under the PAVmed Inc. 2014 Equity Plan, each with a ten year contractual term from date-of-grant, and vesting ratably on a quarterly basis, generally over a 36 month period. PAVmed Inc 2014 Equity Plan - Restricted Stock Awards On March 15, 2019, a total of 700,000 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, representing a corresponding number of shares of common stock of the Company, which vest ratably on an annual basis commencing March 15, 2020 and ending March 15, 2022. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. As of September 30, 2019, no restricted stock awards had vested. PAVmed Inc Employee Stock Purchase Plan The PAVmed Inc. Employee Stock Purchase Plan (“ESPP”), adopted by the Company’s board of directors effective April 1, 2019, with a reservation of 250,000 shares of PAVmed Inc. common stock, provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the “purchase price per share” is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are March 31 and September 30, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019. On September 30, 2019, 82,772 shares of PAVmed Inc. common stock were issued for proceeds of $67,436 under the ESPP. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (the “Lucid Diagnostics Inc. 2018 Equity Plan”) became effective on May 12, 2018 and is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed above. The Lucid Diagnostics Inc. 2018 Equity Plan is designed to enable Lucid Diagnostics Inc. to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of Lucid Diagnostics Inc. The Lucid Diagnostics Inc. 2018 Equity Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics Inc. board of directors. A total of 2,000,000 shares of common stock of Lucid Diagnostics Inc. are reserved for issuance under the Lucid Diagnostics Inc. 2018 Equity Plan, with 1,305,000 shares available for grant as of September 30, 2019, exclusive of 300,000 Lucid Diagnostics Inc. stock options previously granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. Lucid Diagnostics Inc 2018 Equity Plan - Stock Options Lucid Diagnostics Inc. 2018 Equity Plan - Stock Options Number Stock Options Weighted Average Remaining Contractual Outstanding stock options at December 31, 2018 375,000 $ 0.60 Granted 620,000 $ 1.02 Exercised — $ — Forfeited — $ Outstanding stock options at September 30, 2019 995,000 $ 0.86 9.2 Vested and exercisable stock options at September 30, 2019 441,246 $ 0.83 9.1 Unvested stock options at September 30, 2019 553,754 $ 0.88 During the nine months ended September 30, 2019, an aggregate of 620,000 stock options were granted under the Lucid Diagnostics Inc. 2018 Equity Plan, each having a ten year contractual term from date-of-grant, and vesting ratably on a quarterly basis, generally over a 36 month period, except for a grant with 200,000 stock options vesting immediately upon grant, with the remaining 100,000 stock options vesting ratably on a quarterly basis, over a 35 month period. Stock-Based Compensation Expense Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards, for the periods indicated, was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 General and administrative expenses $ 268,859 $ 247,818 $ 852,868 $ 701,174 Research and development expenses 61,374 76,655 324,414 198,475 Total $ 330,233 $ 324,473 $ 1,177,282 $ 899,649 The stock-based compensation expense related to stock options granted to employees and directors is based on the grant-date estimated fair value, and for stock options granted to non-employees is based on the vesting date estimated fair value, with the expense recognized on a straight-line basis over the award’s requisite service period, which is generally the vesting period. The consolidated stock-based compensation expense classified in research and development expenses, as presented above, includes such expense recognized by Lucid Diagnostics Inc. with respect to each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Plan, including $3,247 and $11,552 in the three and nine months ended September 30, 2019, respectively, and $5,329 and $8,962 in the three and nine months ended September 30, 2018, respectively, with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan; and. $8,720 and 141,778 in the three and nine months ended September 30, 2019, respectively, and $12,973 and $21,250 in the three and nine months ended September 30, 2018, respectively, with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan. As of September 30, 2019, total unrecognized stock-based compensation expense and weighted average remaining requisite service period under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, is as follows: Remaining Unrecognized Service Expense Period PAVmed Inc. 2014 Equity Plan Stock Options $ 1.4 million 1.3 years Restricted Stock Awards $ 0.6 million 2.4 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 0.2 million 2.1 years Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to employees and members of the board of directors was based on a weighted average estimated fair value of such stock options of $0.92 and $1.22 per share during the nine months ended September 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.3 % 2.1 % Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 50 % 50 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees was based on a weighted average estimated fair value of such stock options of $1.87 and $2.07 per share during the nine months ended September 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.2 % 2.7 % Expected term of stock options (in years) 8.6 8.8 Expected stock price volatility 60 % 60 % Expected dividend yield 0 % 0 % The restricted stock awards granted to employees under the PAVmed Inc. 2014 Equity Plan are measured at their grant date estimated fair value based on the date-of-grant quoted price per share of PAVmed Inc. common stock. The 700,000 restricted stock awards granted on March 15, 2019 had an aggregate fair value of $742,000, with such stock-based compensation expense recognized ratably over the requisite service period, which is the vesting period, commencing on the March 15, 2019 grant date and ending on the March 15, 2022 final vesting date. The stock-based compensation expense recognized with respect to such restricted stock awards was $61,833 and $144,278 in the three and nine months ended September 30, 2019 was, respectively, and is included in the consolidated stock-based compensation expense classified in general and administrative expenses, as presented above. There was no such stock-based compensation expense in the corresponding prior year period. Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to employees was based on a weighted average estimated fair value of such stock options of $0.32 and $0.40 per share during the three and nine months ended September 30, 2019 and 2018, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 Risk free interest rate 2.1 % Expected term of stock options (in years) 5.8 Expected stock price volatility 63 % Expected dividend yield 0 % There was no stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to employees in the corresponding prior year period. Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to non-employees was based on a weighted average estimated fair value of such stock options of $0.36 and $0.40 per share during the three and nine months ended September 30, 2019 and 2018, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, September 30, 2019 2018 Risk free interest rate 2.0 % 3.0 % Expected term of stock options (in years) 9.0 9.7 Expected stock price volatility 62 % 66 % Expected dividend yield 0 % 0 % As noted above, the Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, which requires the Company to make certain estimates and assumptions, with the weighted-average valuation assumptions for stock-based awards, as follows: weighted-average risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period commensurate with the assumed expected option term; expected term of stock options represents the period of time stock options are expected to be outstanding, which for employees is the expected term derived using the simplified method and for non-employees is the contractual term; expected stock price volatility is based on historical stock price volatilities of similar entities within the Company’s industry over the period commensurate with the expected term of the stock option; and, expected dividend yield is based on annual dividends of $0.00 as the Company has not historically paid, and does not expect to pay dividends for the foreseeable future. The PAVmed Inc. quoted closing price per share of common stock is used in the computation of estimated fair value of stock options granted under the PAVmed Inc. 2014 Equity Plan. The price per share common stock of Lucid Diagnostics Inc. used in the computation of estimated fair value of stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was estimated using a discounted cash flow method applied to a multi-year forecast of future cash flows of Lucid Diagnostics Inc.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 5 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total September 30, 2019 Senior Secured Convertible Note $ — $ — $ 4,471,535 $ 4,471,535 Totals $ — $ — $ 4,471,535 $ 4,471,535 December 31, 2018 Senior Secured Convertible Note $ — $ — $ 7,903,000 $ 7,903,000 Totals $ — $ — $ 7,903,000 $ 7,903,000 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. Senior Secured Convertible Note - December 2018 The Senior Secured Convertible Note issued December 27, 2018 estimated fair value and face value principal, and the corresponding changes in estimated fair value and face value principal payable, as of each of the respective dates noted, are as follows: Senior Secured Convertible Note - Issued December 27, 2018 Nine Months Ended September 30, 2019 Fair Value Face Value Principal Payable Balances - December 31, 2018 $ 7,903,000 $ 7,750,000 Less: repayment - bi-monthly Installment Amount - common stock (1,162,500 ) (1,162,500 ) Less: repayment - Accelerated Installment Amount - common stock (904,500 ) (904,500 ) Less: repayment - voluntary conversion price adjustments - common stock (1,314,000 ) (1,314,000 ) Less: bi-monthly non-installment payments - cash (279,002 ) — Less: non-installment payments - common stock (112,293 ) — Fair value adjustment - nine months ended September 30, 2019 340,830 — Balances - September 30, 2019 $ 4,471,535 $ 4,369,000 Senior Secured Convertible Note - Issued December 27, 2018 Face Value Principal December 27, 2018 to December 31, 2018 Fair Value Payable Balances - issue date December 27, 2018 $ 7,750,000 $ 7,750,000 Fair value adjustment - December 27, 2018 to December 31, 2018 153,000 — Balances - December 31, 2018 $ 7,903,000 $ 7,750,000 In the nine months ended September 30, 2019, the aggregate face value principal repayments of $3,381,000 and $112,293 of corresponding non-installment payments were settled by the issue of a total of 3,850,427 shares of common stock of the Company, and an additional non-installment payments of $279,002 were cash paid. The fair value adjustment of $340,830 as of September 30, 2019 was recognized as a current period expense in the nine months ended September 30, 2019, as no portion of such fair value adjustments resulted from instrument-specific credit risk of the Senior Secured Convertible Note, as of the dates noted. The estimated fair value as of September 30, 2019 and December 31, 2018 of the Senior Secured Convertible Note was computed using a combination of the present value of the Senior Secured Convertible Note cash flows using a synthetic credit rating analysis’ required rate of return and the Black-Scholes option pricing model, using the following assumptions: Fair Value Assumptions September 30, December 31, Senior Secured Convertible Note - Issued December 27, 2018 2019 2018 Fair value $ 4,471,535 $ 7,903,000 Face value principal payable $ 4,369,000 $ 7,750,000 Required rate of return 12.3 % 13.1 % Conversion price $ 1.60 $ 1.60 Value of common stock $ 0.96 $ 0.96 Expected term (years) 0.9 2.0 Volatility 56 % 50 % Risk free rate 1.75 % 2.5 % Dividend yield 0 % 0 % See Note 6, Debt

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	Note 6 — Debt Senior Secured Convertible Note - December 2018 In a private placement transaction with an institutional investor (“Investor”, “Lender”, and /or “Holder”) on December 27, 2018, the Company entered into a Securities Purchase Agreement under which it issued a Senior Secured Convertible Note, having an issue date of December 27, 2018, a contractual maturity date of December 31, 2020, a face value principal of $7.75 million, and a stated interest rate of 7.875% per annum - referred to herein as the “December 2018 Senior Convertible Note”. At the election of the Holder, the December 2018 Senior Convertible Note may be converted into shares of common stock of the Company, as discussed below. The December 2018 Senior Convertible Note proceeds were $7.0 million after payment of $750,000 of lender fees. The Company incurred total offering costs of $614,940, inclusive of the payment of a $455,000 placement agent fee and legal fees, with such offering costs recognized as a current period expense on December 27, 2018. Bi-Monthly Payments & Conversion The December 2018 Senior Convertible Note requires bi-monthly payments on the 15th calendar day and the last trading day of the month, commencing January 15, 2019 and ending December 31, 2020, including a contractually stated face value principal repayment, referred to as a bi-monthly Installment Amount, and a payment based on the outstanding face value principal and the 7.875% annual interest rate, referred to herein as a bi-monthly non-installment payment. The bi-monthly payments of January 15, 2019 through June 15, 2019 were non-installment payments only, and the bi-monthly payments from June 28, 2019 through December 31, 2020 include both the Installment Amount and the non-installment payment. As originally structured, the December 2018 Senior Convertible Note Installment Amount included 35 bi-monthly payments of $193,750 from June 28, 2019 through November 30, 2020, and two final payments of $484,375 on each of December 15, 2020 and December 31, 2020, with such bi-monthly dates referred to as Installment Dates. Notwithstanding, future contractual Installment Amounts are reduced by additional face value principal repayments, with the reductions applied in reverse order of maturity of the bi-monthly Installment Amounts, starting with the final December 31, 2020 bi-monthly Installment Amount. In this regard, as of September 30, 2019, the future bi-monthly Installment Amounts have been reduced by an aggregate of $2,218,500 resulting from conversions in excess of the contractual bi-monthly Installment Amount, including a series of “conversion price voluntary adjustments” and the “Accelerated Installment Amount”, each as discussed below. At the election of the Holder, at any time after the December 27, 2018 issue date, the December 2018 Senior Convertible Note may be converted into shares of common stock of the Company at an initial contractual conversion price of $1.60 per share. As amended on April 11, 2019, commencing with the June 28, 2019 bi-monthly payment, the bi-monthly Installment Amount and non-installment payment will be paid by the issue of shares of common stock of the Company, subject to the satisfaction of customary equity conditions, including minimum price and volume thresholds, referred to as an Installment Conversion. In addition to the bi-monthly Installment Amount, the Holder may elect to accelerate the conversion of future bi-monthly Installment Amounts, and interest thereon, referred to herein as an Acceleration Installment Amount, utilizing the then current conversion price of the most recent bi-monthly Installment Conversion, with such Accelerated Installment Amount subject to certain restrictions, as defined. The December 2018 Senior Convertible Note provides for a voluntary adjustment of the conversion price at the discretion of the Company, with the consent of the Holder, wherein during the term of the December 2018 Senior Convertible Note, the Company may at any time reduce the then current conversion price to any amount and for any period of time deemed appropriate by the board of directors of the Company. The Company’s board of directors have adopted guidelines surrounding such a December 2018 Senior Convertible Note voluntary adjustment of the conversion price, if any, to be implemented by management when favorable market conditions exist for the Company to orderly and effectively reduce its outstanding debt to the investor. See below for a discussion of the conversion price voluntary adjustments. Measurement and Recognition The December 2018 Senior Convertible Note is a debt host containing embedded features and /or options generally required to be bifurcated from the debt host and recognized as separate derivatives subject to initial and subsequent periodic estimated fair value measurements under FASB Topic ASC 815, Derivatives and Hedging Financial Instruments Financial Instruments Fair Value Measurements The December 2018 Senior Convertible Note fair value adjustments resulted in the recognition of income $379,229 and an expense of $340,830 in the three and nine months ended September 30, 2019, respectively. As the December 2018 Senior Convertible Note was issued on December 27, 2018, there is no such fair value adjustment recognized in the corresponding prior year periods of three and nine months ended September 30, 2018. In the three nine months ended September 30, 2019, the aggregate principal repayments of $1,850,000 and $3,381,000, respectively, and 89,332 and $112,293 of corresponding non-installment payments, respectively, were settled by the issue of 2,334,186 and 3,850,427 shares of common stock of the Company, respectively, resulting in a debt extinguishment loss in the three and nine months ended September 30, 2019, of $406,858 and $666,670, respectively, summarized as follows: Three Nine Months Months Ended Ended September 30, September 30, 2019 2019 Bi-monthly Installment Amount principal repayments $ 968,750 $ 1,162,500 Accelerated Installment Amount principal repayments 881,250 904,500 Voluntary conversion price adjustments principal repayments — 1,314,000 Sub-Total: principal repayments 1,850,000 3,381,000 Non-installment payments 89,332 112,293 Total Installment repayments and Non-Installment payments $ 1,939,332 $ 3,493,293 Fair Value - Common Stock Issued $ 2,346,190 $ 4,159,963 Debt Extinguishment Loss $ 406,858 $ 666,670 As noted above, the debt extinguishment loss resulted from the difference between the total of the bi-monthly Installment Amount principal repayments and the Accelerated Amount principal repayments and corresponding non-installment payments, as compared to the fair value of the shares of common stock issued upon such conversions, with the common stock fair value measured as the respective issue date closing quoted price per share of the common stock of the Company. As provided for in the December 2018 Senior Secured Convertible Note Agreement, the Holder elected to defer the September 30, 2019 bi-monthly Installment Amount, as well as, subsequent to September 30, 2019, the Installment Amount for each of the October 15, 2019 and October 31, 2019 bi-month Installment Dates. Subsequent to September 30, 2019 and through November 12, 2019, total Acceleration Installment Amount face value principal repayments of $150,000 and the corresponding $1,641 of non-installment payment, was settled by the issue of 202,950 shares of common stock of the Company with a fair value of $184,864, with the common stock fair value measured as the respective issue date closing quoted price per share of the common stock of the Company. Covenants and Other Provisions Under the December 2018 Senior Convertible Note, the Company is subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets, and to have an unrestricted cash balance of at least $1.75 million at each quarterly balance sheet date, among other provisions and covenants. Senior Secured Note - July 2017 On December 27, 2018, concurrent with the issue of the December 2018 Senior Convertible Note, the Company repaid-in-full the previously issued Senior Secured Note. The Senior Secured Note total interest expense recognized was $707,714 and $1,708,322, respectively, in the three and nine months ended September 30, 2018. The total interest expense was comprised of: the Senior Secured Note stated 15% interest expense of $201,867 and $591,007, respectively; and debt discount amortization of $505,847 and $1,117,315, respectively, for the three and nine months ended September 30, 2018.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Preferred Stock	Note 7 — Preferred Stock The Company is authorized to issue 20 million shares of its preferred stock, par value of $0.001 per share, with such designation, rights, and preferences as may be determined from time-to-time by the Company’s board of directors. There were 1,135,482 and 1,069,941 shares of Series B Convertible Preferred Stock (classified in permanent equity) issued and outstanding as of September 30, 2019 and December 31, 2018, respectively. During the nine months ended September 30, 2019, the Company’s board-of-directors have declared Series B Convertible Preferred Stock dividend payments totaling $196,470 which have been settled by the issue of an additional 65,541 shares of Series B Convertible Preferred Stock, including: dividends earned as of June 30, 2019 and payable July 1, 2019 of $66,792 settled by the issue of an additional 22,281 shares of Series B Convertible Preferred Stock. Subsequently, in October 2019, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend payment earned as of September 30, 2019 and payable October 1, 2019 of $68,129 to be settled by the issue of an additional 22,727 shares of Series B Convertible Preferred Stock. The October 1, 2019 Series B Convertible Preferred Stock dividend payment was not recognized as a dividend payable liability in the accompanying unaudited condensed consolidated balance sheet as the Company’s board of directors had not declared such dividends payable as of September 30, 2019.

Stockholders' Equity and Common

Stockholders' Equity and Common Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity and Common Stock Purchase Warrants	Note 8 — Stockholders’ Equity and Common Stock Purchase Warrants Common Stock As of September 30, 2019 the Company is authorized to issue up to 100.0 million shares of common stock, par value of $0.001 per share. There were 36,556,178 and 27,142,979 shares of common stock issued and outstanding as of September 30, 2019 and December 31, 2018, respectively, summarized as follows: Shares of Common Stock Issued and Outstanding Issued and outstanding as of December 31, 2018 27,142,979 Registered offerings 5,480,000 Conversions - Senior Secured Convertible Note issued December 27, 2018 3,850,427 Employee Stock Purchase Plan (“ESPP”) 82,772 Issued and outstanding as of September 30, 2019 36,556,178 ● A total of 5,480,000 shares of common stock of the Company were issued in registered offerings, including 4,950,000 shares issued under common stock share subscription agreements entered into with individual investors and 530,000 shares issued under a placement agency agreement, resulting in total proceeds of $5,480,000, before placement agent fees and legal fees of $101,098. ● A total of 3,850,427 shares of common stock of the Company were issued upon conversions of the December 2018 Senior Secured Convertible Note. See Note 6, Debt, ● A total of 82,772 shares of common stock of the Company were issued under the PAVmed Inc. Employee Stock Purchase Plan (“ESPP”). See Note 4, Stock-Based Compensation, Subsequent to September 30, 2019, through November 12, 2019, an additional 202,950 shares of common stock of the Company were issued upon conversions of the December 2018 Senior Secured Convertible Note. See Note 6, Debt, Common Stock Purchase Warrants The following table summarizes outstanding warrants to purchase common stock of the Company at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at September 30, 2019 Weighted Average Exercise Price /Share December 31, 2018 Weighted Average Exercise Price Expiration Equity classified warrants Series Z Warrants 16,815,039 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants 1,199,383 $ 0.01 1,199,383 $ 0.01 June 2032 Total 18,449,240 $ 1.57 18,449,240 $ 1.57 Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Nine Months Ended September 30, 2019 Year Ended December 31, 2018 NCI - equity (deficit) - beginning of period $ (161,512 ) $ — Investment in majority-owned subsidiary — 1,812 Net loss attributable to NCI (500,622 ) (204,072 ) Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation 141,778 40,748 NCI - equity (deficit) - end of period $ (520,356 ) $ (161,512 ) The noncontrolling interest presented above is with respect to Lucid Diagnostics Inc., a majority-owned subsidiary of PAVmed Inc., formed in May 2018 in connection with the “CWRU License Agreement”. As of September 30, 2019 and December 31, 2018, there were 10.0 million shares of common stock of Lucid Diagnostics Inc. issued and outstanding, of which PAVmed Inc. holds a 81.875% majority-interest ownership and has a controlling financial interest, with the remaining 18.125% minority-interest ownership held by CWRU and each of the three physician inventors of the intellectual property and proprietary technologies underlying the CWRU License Agreement. Accordingly, a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity, along with the recognition of a net loss attributable to the NCI. In this regard, the daily operations of Lucid Diagnostics Inc. are managed by personnel employed by PAVmed Inc. The costs for such personnel are reimbursed from Lucid Diagnostics Inc. to PAVmed Inc. according to the provisions of a Master Services Agreement (“MSA”) between the parties. Lucid Diagnostics Inc. recognized expenses required to be paid to PAVmed Inc. under the MSA of $600,000 and $90,000 for the nine months ended September 30, 2019 and 2018, respectively. The pro-rata portion of these expenses related to the minority-interest ownership are included in the net loss attributable to NCI as presented above.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Loss Per Share	Note 9 —Loss Per Share The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Numerator Net loss - before noncontrolling interest $ (3,271,309 ) $ (3,278,658 ) $ (10,714,055 ) $ (11,250,567 ) Net loss attributable to noncontrolling interest 186,349 32,431 500,622 113,631 Net loss - as reported, attributable to PAVmed Inc. $ (3,084,960 ) $ (3,246,227 ) $ (10,213,433 ) $ (11,136,936 ) Convertible Preferred Stock dividends (1) Series B $ (68,129 ) $ (64,897 ) $ (200,402 ) $ (138,926 ) Series A-1 — — — (25,148 ) Series A — — — (26,487 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock Net loss attributable to PAVmed Inc. common stockholders $ (3,153,089 ) $ (3,311,124 ) $ (10,413,835 ) $ (11,854,787 ) Denominator Weighted average common shares outstanding basic and diluted (2) (3) 31,030,929 26,538,632 29,211,694 20,827,519 Loss per share Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. $ (0.10 ) $ (0.12 ) $ (0.35 ) $ (0.53 ) - Net loss attributable to PAVmed Inc. common stockholders $ (0.10 ) $ (0.12 ) $ (0.36 ) $ (0.57 ) (1) The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to September 30, 2018, and for each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. (2) Basic weighted average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. (3) The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses. The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: September 30, 2019 2018 Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan 5,853,529 3,277,140 Unit purchase options - “UPO-Z” /“UPO-W” - as to shares of common stock 53,000 53,000 Unit purchase options - “UPO-Z” - as to shares underlying Series Z Warrants 53,000 53,000 Series Z Warrants 16,815,039 16,815,039 Series W Warrants 381,818 381,818 Series S Warrants* — 1,199,383 Series B Convertible Preferred Stock 1,135,482 1,048,288 Total 24,291,868 22,827,668 * The Series S Warrants were not included in weighted average shares outstanding in the three and nine months ended September 30, 2018 due to certain restrictions on beneficial ownership of the Holder which had not lapsed until January 2019.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 10 — Subsequent Events Senior Secured Convertible Note - November 2019 On November 3, 2019, PAVmed Inc. entered into a Securities Purchase Agreement (“SPA”) with two institutional investors, and pursuant to the SPA, on November 4, 2019 the Company consummated the sale of two series of Senior Secured Convertible Notes in a private placement with a $14.0 million aggregate face value principal referred to herein as the “November 2019 Senior Convertible Notes”. As discussed below, the November 2019 Senior Convertible Notes were further divided in a Series A and Series B, each with a face value principal of $7.0 million. The Series A and Series B Senior Convertible Notes were issued with an original issue discount “OID” aggregate total of $700,000 for each note series. With respect to the Series A Senior Convertible Note, the investors delivered to the Company cash proceeds of $6.3 million at closing. Additionally, the Company paid an advisory fee of $409,500 to the placement agent, representing 6.5% of the closing cash proceeds. The SPA contains certain representations and warranties, covenants, and indemnities customary for similar transactions. The Notes are senior secured obligations of the company secured by a lien on all assets. One of the aforementioned institutional investor is also party to a previous Securities Purchase Agreement with the Company dated December 27, 2018, pursuant to which, among other things the Company issued to the existing investor the Senior Secured Convertible Note issued December 27, 2018 as discussed above in Note 6, Debt With respect to the Series B Senior Convertible Note, the investors delivered to the Company secured promissory notes with a total principal amount of $6.3 million, with such promissory notes referred to herein as the “Investor Notes”. Until such time that the Investor Notes are paid in cash to the Company, they will be considered restricted and are prohibited from being converted into common shares of the Company. The Series B Investor Notes are subject to optional prepayment by each investor at any time at the option of the investor, and mandatory prepayment, at the Company’s option, subject to certain equity conditions including, among other conditions, the effectiveness of a resale registration statement. If the respective Series B Investor Notes are each subsequently satisfied by payment in cash, the Company will incur additional financial advisory fees of $409,500. A bi-monthly principal repayment and corresponding interest payment will be due commencing March 30, 2020, and then on each of the successive 15th day of the month and the last trading day of the month, and on the maturity date (each, an “Installment Date”). On each bi-monthly Installment Date, the Company will be required to settle a principal repayment totaling $189,190 for the Series A notes, and to the extent the company has received full cash payment for the Investor Notes, $189,190 for the Series B notes, together with interest thereon, referred to herein as the “Installment Amount”, which shall be satisfied in shares of common stock of the Company, subject to customary equity conditions (including minimum price and volume thresholds), at 100% of the Installment Amount (an “Installment Conversion”), or otherwise (or at our option, in whole or in part) in cash at 115% of the Installment Amount (an “Installment Redemption”). Generally, an Installment Amount will be automatically deferred to the extent due in respect of restricted principal under the Series B Notes until the corresponding portion of the Investor Note has been prepaid to the Company in cash Under certain conditions, the Investor or the Company, may offset the Series B notes against the Investor notes. The Series A Convertible Note and the Series B Convertible Note each have a stated interest rate of 7.875% per annum, except the restricted amounts under each Series B Convertible Note have an interest rate of 3.0% per annum until becoming unrestricted as describe above, then such interest rate is 7.875%. The Series A Convertible Note and the unrestricted amount of the Series B Convertible Note is convertible, at the option of the noteholder, into shares of common stock of the Company at a conversion price of $1.60 per share, with such conversion price subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction. Solys Diagnostics Inc. On October 7, 2019, PAVmed Inc. formed Solys Diagnostics Inc. (DE) with authorization to issue 50 million shares of its common stock, par value $0.001 per share and 20 million shares of its preferred stock, par value $0.001 per share. Concurrent with its formation, Solys Diagnostics Inc. issued 8.5 million shares of its common stock to PAVmed, Inc. and also immediately acquired a license agreement from Liquid Sensing, Inc., a subsidiary of Airware, Inc., each an unrelated-third-party, in exchange for 1.5 million shares of Solys Diagnostics Inc. common stock issued to Airware, Inc., and 200,000 shares of Solys Diagnostics Inc. common shares issued to a unrelated-third-party consultant. Airware Inc. equity interests have certain anti-dilution rights under limited circumstances and 810,810 shares of Solys Diagnostics Inc. common stock issued to Airware Inc. are subject to certain milestone vesting restrictions. PAVmed Inc. and Airware Inc. have entered into a shareholder’s agreement which, among other customary terms, limits certain transfers of their respective ownership interests in Solys Diagnostics Inc. The exclusive worldwide licensing agreement acquired from Liquid Sensing, Inc. is for its six issued and one pending U.S. patents covering a nondispersive infrared (NDIR) laser proprietary technology for the non-invasive detection of glucose and other substances such as electrolytes in tissue within the inpatient (e.g. hospital) field of use. Pursuant to the licensing agreement, Solys Diagnostics Inc. will immediately advance the technology toward an established accuracy milestone for blood glucose monitoring within the licensed field of use. Upon achievement of the accuracy milestone, it is expected Solys Diagnostics Inc. will then pursue a full regulatory and development plan while also seeking to maximize the value of this proprietary technology with potential strategic partners or acquirers in the blood glucose monitoring market. If commercialized by Solys Diagnostics Inc., Liquid Sensing Inc. has the right to collect future royalties on revenues related to the product developed for commercial use. Liquid Sensing Inc. has granted a 15 percent equity interest in its company to PAVmed, Inc. with a portion of the shares issued being subject to certain performance vesting restrictions. Other Matters Except as otherwise noted herein, the Company has evaluated subsequent events through the date of filing of this Quarterly Report on Form 10-Q and determined there to be no further events requiring adjustments to the unaudited condensed unaudited condensed consolidated financial statements and /or disclosures therein.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the minority ownership interest in the Company’s majority-owned subsidiary Lucid Diagnostics Inc. and the corresponding noncontrolling interest. The condensed balance sheet as of December 31, 2018, which has been derived from audited financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and related notes thereto as of and for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC.
Going Concern	Going Concern The provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Presentation of Financial Statements - Going Concern The Company anticipates incurring operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating losses as it completes the development of its products, seeks regulatory approvals and clearances of such products, and begin to commercially market such products. These factors, which have existed since inception, are expected to continue, and raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued. The Company’s ability to fund its operations is dependent upon management’s plans, which include raising additional capital, refinance the debt upon maturity, obtaining regulatory approvals for its products currently under development, commercializing and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance the Company will be successful in these efforts. The Company’s unaudited condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern.
Recent Accounting Standards	Recent Accounting Standards Adoption of new accounting Standard In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) Recently issued accounting standards, not yet adopted: In June 2018, the FASB issued its Accounting Standards Update (“ASU”) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07), which, upon the effective date, will result in non-employee stock-based compensation to be within the scope of ASC-718, and will supersede ASC 505-50. A principal change of the new guidance is to eliminate the ASC 505-50 required periodic fair value remeasure (“mark-to-market”) and use of the “contractual term” as an input to the Black-Scholes option pricing model to calculate the estimated fair value of stock options issued to non-employees, in favor of the ASC 718 one-time measurement of the grant date fair value and use of an “expected term” as such valuation input, for non-employee stock-based compensation expense, as is currently done for employee stock-based compensation expense. The amended ASC-718 non-employee stock-based compensation provisions are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within such fiscal year, and for all other companies for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606). With respect to the Company and its majority-owned subsidiary, the amended ASC-718 non-employee stock-based compensation provisions are required to be adopted by no later than January 1, 2020, resulting from the Company’s “JOBS Act EGC Election” as discussed Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Additionally, the Company, under its “JOBS Act EGC Accounting Standards Election”, adopted ASC 606 as of January 1, 2019, which is the required adoption date of ASC 606 for private companies. At this time, the Company and its majority-owned subsidiary continue to apply the guidance of ASC-505-50 with respect to non-employee stock-based compensation, subject-to the future adoption date of the amended ASC-718 provisions with respect to non-employee stock-based compensation. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) - Part I - Accounting for Certain Financial Instruments with Down-Round Features, and Part II - Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	PAVmed Inc 2014 Equity Plan - Stock Options PAVmed Inc. 2014 Equity Plan - Stock Options Number Stock Options Weighted Average Exercise Price Aggregate Remaining Contractual Term (Years) Outstanding stock options at December 31, 2018 3,327,140 $ 3.68 $ — Granted 1,875,000 $ 1.00 Exercised — $ — Forfeited (48,611 ) $ 5.00 Outstanding stock options at September 30, 2019 5,153,529 $ 2.70 $ — 8.4 Vested and exercisable stock options at September 30, 2019 2,942,544 $ 3.62 $ — 7.7 Unvested stock options at September 30, 2019 2,210,985 $ 1.46 $ — Lucid Diagnostics Inc 2018 Equity Plan - Stock Options Lucid Diagnostics Inc. 2018 Equity Plan - Stock Options Number Stock Options Weighted Average Remaining Contractual Outstanding stock options at December 31, 2018 375,000 $ 0.60 Granted 620,000 $ 1.02 Exercised — $ — Forfeited — $ Outstanding stock options at September 30, 2019 995,000 $ 0.86 9.2 Vested and exercisable stock options at September 30, 2019 441,246 $ 0.83 9.1 Unvested stock options at September 30, 2019 553,754 $ 0.88
Schedule of Stock-Based Compensation Awards Granted	Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards, for the periods indicated, was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 General and administrative expenses $ 268,859 $ 247,818 $ 852,868 $ 701,174 Research and development expenses 61,374 76,655 324,414 198,475 Total $ 330,233 $ 324,473 $ 1,177,282 $ 899,649
Schedule of Unrecognised Compensation Expense	As of September 30, 2019, total unrecognized stock-based compensation expense and weighted average remaining requisite service period under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, is as follows: Remaining Unrecognized Service Expense Period PAVmed Inc. 2014 Equity Plan Stock Options $ 1.4 million 1.3 years Restricted Stock Awards $ 0.6 million 2.4 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 0.2 million 2.1 years
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to employees and members of the board of directors was based on a weighted average estimated fair value of such stock options of $0.92 and $1.22 per share during the nine months ended September 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.3 % 2.1 % Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 50 % 50 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to employees was based on a weighted average estimated fair value of such stock options of $0.32 and $0.40 per share during the three and nine months ended September 30, 2019 and 2018, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 Risk free interest rate 2.1 % Expected term of stock options (in years) 5.8 Expected stock price volatility 63 % Expected dividend yield 0 %
Non-employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees was based on a weighted average estimated fair value of such stock options of $1.87 and $2.07 per share during the nine months ended September 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.2 % 2.7 % Expected term of stock options (in years) 8.6 8.8 Expected stock price volatility 60 % 60 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to non-employees was based on a weighted average estimated fair value of such stock options of $0.36 and $0.40 per share during the three and nine months ended September 30, 2019 and 2018, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, September 30, 2019 2018 Risk free interest rate 2.0 % 3.0 % Expected term of stock options (in years) 9.0 9.7 Expected stock price volatility 62 % 66 % Expected dividend yield 0 % 0 %

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total September 30, 2019 Senior Secured Convertible Note $ — $ — $ 4,471,535 $ 4,471,535 Totals $ — $ — $ 4,471,535 $ 4,471,535 December 31, 2018 Senior Secured Convertible Note $ — $ — $ 7,903,000 $ 7,903,000 Totals $ — $ — $ 7,903,000 $ 7,903,000 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.
Schedule of Fair Value Assumption Used	The estimated fair value as of September 30, 2019 and December 31, 2018 of the Senior Secured Convertible Note was computed using a combination of the present value of the Senior Secured Convertible Note cash flows using a synthetic credit rating analysis’ required rate of return and the Black-Scholes option pricing model, using the following assumptions: Fair Value Assumptions September 30, December 31, Senior Secured Convertible Note - Issued December 27, 2018 2019 2018 Fair value $ 4,471,535 $ 7,903,000 Face value principal payable $ 4,369,000 $ 7,750,000 Required rate of return 12.3 % 13.1 % Conversion price $ 1.60 $ 1.60 Value of common stock $ 0.96 $ 0.96 Expected term (years) 0.9 2.0 Volatility 56 % 50 % Risk free rate 1.75 % 2.5 % Dividend yield 0 % 0 %
Senior Secured Convertible Note [Member]
Schedule of Senior Convertible Note Estimated Fair Value and Changes in Face Value Principal Payable	The Senior Secured Convertible Note issued December 27, 2018 estimated fair value and face value principal, and the corresponding changes in estimated fair value and face value principal payable, as of each of the respective dates noted, are as follows: Senior Secured Convertible Note - Issued December 27, 2018 Nine Months Ended September 30, 2019 Fair Value Face Value Principal Payable Balances - December 31, 2018 $ 7,903,000 $ 7,750,000 Less: repayment - bi-monthly Installment Amount - common stock (1,162,500 ) (1,162,500 ) Less: repayment - Accelerated Installment Amount - common stock (904,500 ) (904,500 ) Less: repayment - voluntary conversion price adjustments - common stock (1,314,000 ) (1,314,000 ) Less: bi-monthly non-installment payments - cash (279,002 ) — Less: non-installment payments - common stock (112,293 ) — Fair value adjustment - nine months ended September 30, 2019 340,830 — Balances - September 30, 2019 $ 4,471,535 $ 4,369,000 Senior Secured Convertible Note - Issued December 27, 2018 Face Value Principal December 27, 2018 to December 31, 2018 Fair Value Payable Balances - issue date December 27, 2018 $ 7,750,000 $ 7,750,000 Fair value adjustment - December 27, 2018 to December 31, 2018 153,000 — Balances - December 31, 2018 $ 7,903,000 $ 7,750,000

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Repayments of Debt	In the three nine months ended September 30, 2019, the aggregate principal repayments of $1,850,000 and $3,381,000, respectively, and 89,332 and $112,293 of corresponding non-installment payments, respectively, were settled by the issue of 2,334,186 and 3,850,427 shares of common stock of the Company, respectively, resulting in a debt extinguishment loss in the three and nine months ended September 30, 2019, of $406,858 and $666,670, respectively, summarized as follows: Three Nine Months Months Ended Ended September 30, September 30, 2019 2019 Bi-monthly Installment Amount principal repayments $ 968,750 $ 1,162,500 Accelerated Installment Amount principal repayments 881,250 904,500 Voluntary conversion price adjustments principal repayments — 1,314,000 Sub-Total: principal repayments 1,850,000 3,381,000 Non-installment payments 89,332 112,293 Total Installment repayments and Non-Installment payments $ 1,939,332 $ 3,493,293 Fair Value - Common Stock Issued $ 2,346,190 $ 4,159,963 Debt Extinguishment Loss $ 406,858 $ 666,670

Stockholders' Equity and Comm_2

Stockholders' Equity and Common Stock Purchase Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding	Shares of Common Stock Issued and Outstanding Issued and outstanding as of December 31, 2018 27,142,979 Registered offerings 5,480,000 Conversions - Senior Secured Convertible Note issued December 27, 2018 3,850,427 Employee Stock Purchase Plan (“ESPP”) 82,772 Issued and outstanding as of September 30, 2019 36,556,178
Schedule of Outstanding Warrants to Purchase Common Stock	The following table summarizes outstanding warrants to purchase common stock of the Company at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at September 30, 2019 Weighted Average Exercise Price /Share December 31, 2018 Weighted Average Exercise Price Expiration Equity classified warrants Series Z Warrants 16,815,039 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants 1,199,383 $ 0.01 1,199,383 $ 0.01 June 2032 Total 18,449,240 $ 1.57 18,449,240 $ 1.57
Schedule of Noncontrolling Interest	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Nine Months Ended September 30, 2019 Year Ended December 31, 2018 NCI - equity (deficit) - beginning of period $ (161,512 ) $ — Investment in majority-owned subsidiary — 1,812 Net loss attributable to NCI (500,622 ) (204,072 ) Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation 141,778 40,748 NCI - equity (deficit) - end of period $ (520,356 ) $ (161,512 )

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Numerator Net loss - before noncontrolling interest $ (3,271,309 ) $ (3,278,658 ) $ (10,714,055 ) $ (11,250,567 ) Net loss attributable to noncontrolling interest 186,349 32,431 500,622 113,631 Net loss - as reported, attributable to PAVmed Inc. $ (3,084,960 ) $ (3,246,227 ) $ (10,213,433 ) $ (11,136,936 ) Convertible Preferred Stock dividends (1) Series B $ (68,129 ) $ (64,897 ) $ (200,402 ) $ (138,926 ) Series A-1 — — — (25,148 ) Series A — — — (26,487 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock Net loss attributable to PAVmed Inc. common stockholders $ (3,153,089 ) $ (3,311,124 ) $ (10,413,835 ) $ (11,854,787 ) Denominator Weighted average common shares outstanding basic and diluted (2) (3) 31,030,929 26,538,632 29,211,694 20,827,519 Loss per share Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. $ (0.10 ) $ (0.12 ) $ (0.35 ) $ (0.53 ) - Net loss attributable to PAVmed Inc. common stockholders $ (0.10 ) $ (0.12 ) $ (0.36 ) $ (0.57 ) (1) The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to September 30, 2018, and for each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. (2) Basic weighted average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. (3) The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: September 30, 2019 2018 Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan 5,853,529 3,277,140 Unit purchase options - “UPO-Z” /“UPO-W” - as to shares of common stock 53,000 53,000 Unit purchase options - “UPO-Z” - as to shares underlying Series Z Warrants 53,000 53,000 Series Z Warrants 16,815,039 16,815,039 Series W Warrants 381,818 381,818 Series S Warrants* — 1,199,383 Series B Convertible Preferred Stock 1,135,482 1,048,288 Total 24,291,868 22,827,668 * The Series S Warrants were not included in weighted average shares outstanding in the three and nine months ended September 30, 2018 due to certain restrictions on beneficial ownership of the Holder which had not lapsed until January 2019.

The Company and Description o_2

The Company and Description of the Business (Details Narrative)	9 Months Ended
	Sep. 30, 2019Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and development expense	$ 1,519,415	$ 1,172,844	$ 4,375,425	$ 2,884,873
CRO Agreement [Member]
On-account deposit	643,000		643,000
Other current asset	200,000		200,000
Research and development expense	104,000		$ 104,000
Lease Agreement [Member]
Percentage of increase in monthly rent			5.00%
Description monthly lease payment			Month-to-month basis, with a 5% per annum increase in the monthly lease payment effective February 1 of each year, and the lease agreement may be cancelled with three months written notice.
Rent expense	32,992	$ 31,331	$ 98,453	$ 93,675
Lease Agreement [Member] | October 1, 2019 to September 30, 2019 [Member]
Future minimum lease payments	136,000		136,000
Lease Agreement [Member] | October 16, 2019 to September 30, 2020 [Member]
Future minimum lease payments	47,500		47,500
Lease Agreement [Member] | November 1, 2019 to April 30, 2020 [Member]
Future minimum lease payments	$ 47,500		$ 47,500

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	Sep. 30, 2019	Apr. 02, 2019	Mar. 15, 2019	Feb. 18, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock							$ 5,480,000
Stock-based compensation expense					$ 330,233	$ 324,473	1,177,282	899,649
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					61,374	$ 76,655	324,414	$ 198,475
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					$ 61,833		$ 144,278
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock reseved		250,000
Vesting portion of stock		ESPP share purchase dates are March 31 and September 30, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019.
Purchase price per share percentage on ESPP plan		85.00%
Number of common stock issued	82,722
Proceeds from issuance of common stock	$ 67,436
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock reseved	7,951,081				7,951,081		7,951,081
Shares of common stock available for grant of stock options	2,598,406				2,598,406		2,598,406
Number of shares granted outside	500,854				500,854		500,854
Number of options granted							1,875,000
Exercise price per share							$ 1
Contractual term of stock options							10 years
Vesting period							36 months
Number of stock options forfeited							48,611
2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting portion of stock			Annual basis, commencing March 15, 2020 and ending March 15, 2022
Number of restricted stock award granted			700,000
Number of restricted stock award granted, value			$ 742,000
2014 Long Term Incentive Equity Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options							$ 0.92	$ 1.22
2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options							$ 1.87	2.07
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock reseved	2,000,000				2,000,000		2,000,000
Shares of common stock available for grant of stock options	1,305,000				1,305,000		1,305,000
Number of options granted							300,000
Expected dividend yield							$ 0
2018 Long Term Incentive Equity Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options					$ 0.32	$ 0.36	$ 0.40	$ 0.40
2018 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					$ 3,247	$ 5,329	$ 11,552	$ 8,962
2018 Long Term Incentive Equity Plan [Member] | Employees and Non-employees [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense					$ 8,720	$ 12,973	$ 141,778	$ 21,250
2018 Long-Term Incentive Equity Plan [Member] | Vesting Immediately [Member] | Lucid Diagnostics Inc [Member] | February 18, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted							620,000
Vesting period							36 months
Weighted average remaining contractual term of stock options outstanding							10 years
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				200,000
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting on a Quarterly Basis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted				100,000
Vesting period				35 months

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance	3,327,140
Number of Stock Options, Granted	1,875,000
Number of Stock Option, Exercised
Number of Stock Option, Forfeited	(48,611)
Number of Stock Options Outstanding, Ending Balance	5,153,529
Number of Stock Options Vested and exercisable	2,942,544
Number of Stock Options Unvested	2,210,985
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 3.68
Weighted-Average Exercise Price, Granted | $ / shares	1
Weighted-Average Exercise Price, Exercised | $ / shares
Weighted-Average Exercise Price, Forfeited | $ / shares	5
Weighted-Average Exercise Price, Ending Balance | $ / shares	2.70
Weighted-Average Exercise Price, Vested and exercisable | $ / shares	3.62
Weighted-Average Exercise Price, Unvested | $ / shares	$ 1.46
Aggregate Intrinsic Value Outstanding | $
Aggregate Intrinsic Value Outstanding | $
Aggregate Intrinsic Value Vested and exercisable | $
Aggregate Intrinsic Value Unvested | $
2018 Stock Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance	375,000
Number of Stock Options, Granted	620,000
Number of Stock Option, Exercised
Number of Stock Option, Forfeited
Number of Stock Options Outstanding, Ending Balance	995,000
Number of Stock Options Vested and exercisable	441,246
Number of Stock Options Unvested	553,754
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 0.60
Weighted-Average Exercise Price, Granted | $ / shares	1.02
Weighted-Average Exercise Price, Exercised | $ / shares
Weighted-Average Exercise Price, Ending Balance | $ / shares	0.86
Weighted-Average Exercise Price, Vested and exercisable | $ / shares	0.83
Weighted-Average Exercise Price, Unvested | $ / shares	$ 0.88
Vested and exercisable stock options, Remaining Contractual Term (Years)	9 years 2 months 12 days
Unvested stock options, Remaining Contractual Term (Years)	9 years 1 month 6 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 330,233	$ 324,473	$ 1,177,282	$ 899,649
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	268,859	247,818	852,868	701,174
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 61,374	$ 76,655	$ 324,414	$ 198,475

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Unrecognised Compensation Expense (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Employee Stock Option [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 200,000
Remaining Service Period	2 years 1 month 6 days
2014 Long-Term Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 1,400,000
Remaining Service Period	1 year 3 months 19 days
2014 Long-Term Incentive Plan [Member] | Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 600,000
Remaining Service Period	2 years 4 months 24 days

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
2014 Long Term Incentive Equity Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.30%	2.10%
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 9 months 18 days
Expected stock price volatility	50.00%	50.00%
Expected dividend yield	0.00%	0.00%
2014 Long Term Incentive Equity Plan [Member] | Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.20%	2.70%
Expected term of stock options (in years)	8 years 7 months 6 days	8 years 9 months 18 days
Expected stock price volatility	60.00%	60.00%
Expected dividend yield	0.00%	0.00%
2018 Long Term Incentive Equity Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.10%
Expected term of stock options (in years)	5 years 9 months 18 days
Expected stock price volatility	63.00%
Expected dividend yield	0.00%
2018 Long-Term Incentive Equity Plan [Member] | Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.00%	3.00%
Expected term of stock options (in years)	9 years	9 years 8 months 12 days
Expected stock price volatility	62.00%	66.00%
Expected dividend yield	0.00%	0.00%

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Repayments of debt	$ 1,850,000	$ 3,381,000
Debt issuance date		Dec. 27, 2018
Senior Secured Convertible Note [Member]
Debt issuance date		Dec. 27, 2018	Dec. 27, 2018
Securities Purchase Agreement [Member] | Senior Secured Convertible Note [Member]
Repayments of debt	1,850,000	$ 3,381,000
Non installment payments settles by shares	$ 89,332	$ 112,293
Non installment payments settles - common shares	2,334,186	3,850,427
Additional Cash paid		$ 279,002
Fair value of adjustment of convertible debt	$ 340,830	$ 340,830
Debt issuance date		Dec. 27, 2018

Financial Instruments Fair Va_4

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)		Sep. 30, 2019	Dec. 31, 2018
Fair value of liability	[1]	$ 4,471,535	$ 7,903,000
Senior Secured Convertible Note [Member]
Fair value of liability	[1]	4,471,535	7,903,000
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | Senior Secured Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | Senior Secured Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]	4,471,535	7,903,000
Fair Value, Inputs, Level 3 [Member] | Senior Secured Convertible Note [Member]
Fair value of liability	[1]	$ 4,471,535	$ 7,903,000
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.

Financial Instruments Fair Va_5

Financial Instruments Fair Value Measurements - Schedule of Convertible Note Estimated Fair Value and Changes in Face Value Principal Payable (Details) - Senior Secured Convertible Note [Member]	9 Months Ended
	Sep. 30, 2019USD ($)
Fair Value - Beginning	$ 7,903,000
Less: repayment - bi-monthly Installment Amount - common stock	(1,162,500)
Less: repayment - Accelerated Installment Amount - common stock	(904,500)
Less: repayment - voluntary conversion price adjustments - common stock	(1,314,000)
Less: bi-monthly non-installment payments - cash	(279,002)
Less: non-installment payments - common stock	(112,293)
Fair value adjustment	340,830
Fair Value - Ending	4,471,535
Face Value Principal Payable - Beginning	7,750,000
Less: repayment - bi-monthly Installment Amount - common stock	(1,162,500)
Less: repayment - Accelerated Installment Amount - common stock	(904,500)
Less: repayment - voluntary conversion price adjustments - common stock	(1,314,000)
Less: bi-monthly non-installment payments - cash
Less: bi-monthly non-installment payments - common stock
Fair value adjustment
Face Value Principal Payable - Ending	$ 4,369,000

Financial Instruments Fair Va_6

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Value of common stock	$ 0.001	$ 0.001
Senior Secured Convertible Note [Member]
Fair value	$ 4,471,535	$ 7,903,000
Face value principal payable	$ 4,369,000	$ 7,750,000
Conversion price	$ 1.60	$ 1.60
Value of common stock	$ 0.96	$ 0.96
Expected term (years)	10 months 25 days	2 years
Senior Secured Convertible Note [Member] | Measurement Input, Required Rate of Return [Member]
Fair value assumptions, measurement input, percentages	12.30%	13.10%
Senior Secured Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	56.00%	50.00%
Senior Secured Convertible Note [Member] | Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	1.75%	2.50%
Senior Secured Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0.00%	0.00%

Financial Instruments Fair Va_7

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) (Parenthetical)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Debt issuance date	Dec. 27, 2018
Senior Secured Convertible Note [Member]
Debt issuance date	Dec. 27, 2018	Dec. 27, 2018

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Nov. 12, 2019	Dec. 27, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Change in fair value - Senior Secured Convertible Note			$ 379,229		$ (340,830)
Repayments of debt			$ 1,850,000		$ 3,381,000
Common stock, shares authorized			100,000,000		100,000,000		100,000,000
Interest expense				707,714		1,708,322
Senior Secured Convertible Note [Member]
Face value principal			$ 4,369,000		$ 4,369,000		$ 7,750,000
Conversion price			$ 1.60		$ 1.60		$ 1.60
Senior Secured Note [Member]
Interest expense				707,714		1,708,322
15% Interest Expense Senior Secured Note [Member]
Interest expense				201,867		$ 591,007
Interest expenses percentage						15.00%
Amortization of debt discount				$ 505,847		$ 1,117,315
Securities Purchase Agreement [Member] | Senior Secured Convertible Note [Member]
Debt instrument maturity date		Dec. 31, 2020
Face value principal		$ 7,750,000
Interest rate		7.875%
Proceeds from senior convertible note		$ 7,000,000
Lender fees		750,000
Offering costs		614,940
Placement agent fee and legal fees		$ 455,000
Annual interest rate on bi-monthly payments		7.875%
Reduction in bi-monthly payments resulting from conversion					$ 2,218,500
Conversion price		$ 1.60
Change in fair value - Senior Secured Convertible Note			$ 379,229		340,830
Repayments of debt			1,850,000		3,381,000
Non installment payments settles by shares			$ 89,332		$ 112,293
Non installment payments settles - common shares			2,334,186		3,850,427
Debt extinguishment loss			$ 406,858		$ 666,670
Covenants and other provisions, description					The Company is subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets, and to have an unrestricted cash balance of at least $1.75 million at each quarterly balance sheet date, among other provisions and covenants.
Covenants and other provisions unrestricted cash balance			$ 1,750,000		$ 1,750,000
Common stock, shares authorized		75,000,000	100,000,000		100,000,000
Securities Purchase Agreement [Member] | Senior Secured Convertible Note [Member] | Subsequent Event [Member]
Repayments of debt	$ 150,000
Non installment payments settles by shares	$ 1,641
Non installment payments settles - common shares	202,950
Fair value of adjustment of convertible debt	$ 184,864
Securities Purchase Agreement [Member] | Senior Convertible Note [Member] | June 28, 2019 Through November 30, 2020 [Member]
Bi-monthly installment payments					$ 193,750
Securities Purchase Agreement [Member] | Senior Convertible Note [Member] | December 15, 2020 [Member]
Bi-monthly installment payments					484,375
Securities Purchase Agreement [Member] | Senior Convertible Note [Member] | December 31, 2020 [Member]
Bi-monthly installment payments					$ 484,375

Debt - Schedule of Repayments o

Debt - Schedule of Repayments of Debt (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Debt Disclosure [Abstract]
Bi-monthly Installment Amount principal repayments	$ 968,750	$ 1,162,500
Accelerated Installment Amount principal repayments	881,250	904,500
Voluntary conversion price adjustments principal repayments		1,314,000
Sub-Total: principal repayments	1,850,000	3,381,000
Non-installment payments	89,332	112,293
Total Installment repayments and Non-Installment payments	1,939,332	3,493,293
Fair Value - Common Stock Issued	2,346,190	4,159,963
Debt Extinguishment Loss	$ 406,858	$ 666,670

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 31, 2019	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, shares authorized			20,000,000	20,000,000
Preferred stock par value			$ 0.001	$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred stock dividend		$ 66,792	$ 196,470
Preferred stock dividend, settled in shares		22,281	65,541
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]
Preferred stock dividend	$ 68,129
Preferred stock dividend, settled in shares	22,727
Series B Convertible Preferred Stock [Member]
Preferred stock par value			$ 0.001	$ 0.001
Convertible preferred stock, shares issued			1,135,482	1,069,941
Preferred stock, shares outstanding			1,135,482	1,069,941

Stockholders' Equity and Comm_3

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)	Nov. 12, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Common stock, shares authorized		100,000,000		100,000,000		100,000,000
Common stock, par value per share		$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued		36,556,178		36,556,178		27,142,979
Common stock, shares outstanding		36,556,178		36,556,178		27,142,979
Number of shares issued				5,480,000
Gross proceeds from issuance of common stock				$ 5,480,000
Placement agent fees and legal fees				$ 101,098
Senior secured convertible note conversion, shares issued				3,850,427
Debt issuance date				Dec. 27, 2018
Number of stock issed under Employee Stock Purchase Plan				82,772
Stock-based compensation		$ 330,233	$ 324,473	$ 1,177,282	899,649
Lucid Diagnostics Inc [Member]
Common stock, shares issued		10,000,000		10,000,000		10,000,000
Common stock, shares outstanding		10,000,000		10,000,000		10,000,000
Majority ownership interest percentage		81.875%		81.875%		81.875%
Common Stock [Member]
Number of shares issued				5,480,000
Noncontrolling Interest [Member] | Lucid Diagnostics Inc [Member]
Majority ownership interest percentage		18.125%		18.125%		18.125%
Subsequent Event [Member]
Senior secured convertible note conversion, shares issued	202,950
Placement Agency Agreement [Member]
Number of shares issued				530,000
Management Services Agreement [Member]
Stock-based compensation				$ 600,000	$ 90,000
Individual Investors [Member]
Number of shares issued				4,950,000

Stockholders' Equity and Comm_4

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding (Details)	9 Months Ended
	Sep. 30, 2019shares
Equity [Abstract]
Shares of Common Stock Issued and Outstanding, beginning balance	27,142,979
Registered offerings	5,480,000
Senior Secured Convertible Note conversion	3,850,427
Employee Stock Purchase Plan ("ESPP")	82,772
Shares of Common Stock Issued and Outstanding, ending balance	36,556,178

Stockholders' Equity and Comm_5

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Debt issuance date	Dec. 27, 2018

Stockholders' Equity and Comm_6

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Outstanding Warrants to Purchase Common Stock (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Warrants [Member]
Warrant issued and outstanding	18,449,240	18,449,240
Warrant, weighted average exercise price	$ 1.57	$ 1.57
Equity Classified Warrants [Member] | Series Z Warrants [Member]
Warrant issued and outstanding	16,815,039	16,815,039
Warrant, weighted average exercise price	$ 1.60	$ 1.60
Warrant expiration date	Apr. 30, 2024	Apr. 30, 2024
Equity Classified Warrants [Member] | UPO - Series Z Warrants [Member]
Warrant issued and outstanding	53,000	53,000
Warrant, weighted average exercise price	$ 1.60	$ 1.60
Warrant expiration date	Jan. 31, 2022	Jan. 31, 2022
Equity Classified Warrants [Member] | Series W Warrants [Member]
Warrant issued and outstanding	381,818	381,818
Warrant, weighted average exercise price	$ 5	$ 5
Warrant expiration date	Jan. 31, 2022	Jan. 31, 2022
Equity Classified Warrants [Member] | Series S Warrants [Member]
Warrant issued and outstanding	1,199,383	1,199,383
Warrant, weighted average exercise price	$ 0.01	$ 0.01
Warrant expiration date	Jun. 30, 2032	Jun. 30, 2032

Stockholders' Equity and Comm_7

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
NCI - equity (deficit) - beginning of period			$ (161,512)
Net loss attributable to NCI	$ (186,349)	$ (32,431)	(500,622)	$ (113,631)
NCI - equity (deficit) - end of period	(520,356)		(520,356)		$ (161,512)
Noncontrolling Interest [Member]
NCI - equity (deficit) - beginning of period			(161,512)
Investment in majority-owned subsidiary					1,812
Net loss attributable to NCI			(500,622)		(204,072)
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation			141,778		40,748
NCI - equity (deficit) - end of period	$ (520,356)		$ (520,356)		$ (161,512)

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (3,271,309)	$ (3,278,658)	$ (10,714,055)	$ (11,250,567)
Net loss attributable to noncontrolling interest		186,349	32,431	500,622	113,631
Net loss - as reported, attributable to PAVmed Inc.		(3,084,960)	(3,246,227)	(10,213,433)	(11,136,936)
Convertible Preferred Stock dividends Series B	[1]	(68,129)	(64,897)	(200,402)	(138,926)
Convertible Preferred Stock dividends Series A-1	[1]				(25,148)
Convertible Preferred Stock dividends Series A	[1]				(26,487)
Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock					(726,531)
Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock					199,241
Net loss attributable to PAVmed Inc. common stockholders		$ (3,153,089)	$ (3,311,124)	$ (10,413,835)	$ (11,854,787)
Weighted average common shares outstanding basic and diluted	[2],[3]	31,030,929	26,538,632	29,211,694	20,827,519
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.		$ (0.10)	$ (0.12)	$ (0.35)	$ (0.53)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders		$ (0.10)	$ (0.12)	$ (0.36)	$ (0.57)
[1]	The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective peripresented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to September 30, 2018, and for each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018.
[2]	Basic weighted average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
[3]	The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses.

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018
Antidilutive securities excluded from computation of diluted weighted shares outstanding		24,291,868	21,628,285
Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		5,853,529	3,277,140
Unit Purchase Options - "UPO-Z" /"UPO-W" - as to Shares of common stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		53,000	53,000
Unit Purchase Options - "UPO-Z" - as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		53,000	53,000
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		16,815,039	16,815,039
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		381,818	381,818
Series S Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	[1]		1,199,383
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		1,135,482	1,048,288
[1]	The Series S Warrants were not included in weighted average shares outstanding in the three and nine months ended September 30, 2018 due to certain restrictions on beneficial ownership of the Holder which had not lapsed until January 2019.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 04, 2019	Oct. 07, 2019	Sep. 30, 2019	Dec. 31, 2018
Debt principal value			$ 4,369,000	$ 775,000
Debt issuance date			Dec. 27, 2018
Common stock, shares authorized			100,000,000	100,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, shares authorized			20,000,000	20,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Number of shares issued			5,480,000
Subsequent Event [Member] | Solys Diagnostics Inc. [Member]
Common stock, shares authorized		50,000,000
Common stock, par value		$ 0.001
Preferred stock, shares authorized		20,000,000
Preferred stock, par value		$ 0.001
Number of shares issued		8,500,000
Subsequent Event [Member] | Liquid Sensing, Inc. [Member]
Ownership percentage		15.00%
Number of shares issued for acquistion		1,500,000
Subsequent Event [Member] | Airware, Inc. [Member]
Number of shares issued		810,810
Number of shares issued for acquistion		200,000
Subsequent Event [Member] | November 2019 Senior Convertible Notes [Member] | Two Investors [Member] | Series A Senior Convertible Note [Member]
Debt principal value	$ 7,000,000
Proceeds from senior convertible note	6,300,000
Placement agent fees	$ 409,500
Placement agent fees percentage	6.50%
Repayment of debt principal amount	$ 189,190
Debt interest rate	7.875%
Subsequent Event [Member] | November 2019 Senior Convertible Notes [Member] | Two Investors [Member] | Series B Senior Convertible Note [Member]
Debt principal value	$ 7,000,000
Proceeds from senior convertible note	6,300,000
Placement agent fees	409,500
Repayment of debt principal amount	$ 189,190
Debt interest rate	7.875%
Subsequent Event [Member] | November 2019 Senior Convertible Notes [Member] | Two Investors [Member] | Series B Senior Convertible Note [Member] | Until Unrestricted [Member]
Debt interest rate	3.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | November 2019 Senior Convertible Notes [Member] | Two Investors [Member]
Debt principal value	$ 14,000,000
Original issue discount	$ 700,000
Repayment of debt principal description	A bi-monthly principal repayment and corresponding interest payment will be due commencing March 30, 2020, and then on each of the successive 15th day of the month and the last trading day of the month, and on the maturity date (each, an “Installment Date”). On each bi-monthly Installment Date, the Company will be required to settle a principal repayment totaling $189,190 for the Series A notes, and to the extent the company has received full cash payment for the Investor Notes, $189,190 for the Series B notes, together with interest thereon, referred to herein as the “Installment Amount”, which shall be satisfied in shares of common stock of the Company, subject to customary equity conditions (including minimum price and volume thresholds), at 100% of the Installment Amount (an “Installment Conversion”), or otherwise (or at our option, in whole or in part) in cash at 115% of the Installment Amount (an “Installment Redemption”). Generally, an Installment Amount will be automatically deferred to the extent due in respect of restricted principal under the Series B Notes until the corresponding portion of the Investor Note has been prepaid to the Company in cash Under certain conditions, the Investor or the Company, may offset the Series B notes against the Investor notes.
Debt conversion price	$ 1.60